Back to the future! the evolving role of maintenance therapy after hematopoietic stem cell transplantation

Christopher S. Hourigan, Philip McCarthy, Marcos De Lima

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations


Relapse is a devastating event for patients with hematologic cancers treated with hematopoietic stem cell transplantation. In most situations, relapse treatment options are limited. Maintenance therapy offers the possibility of delaying or avoiding disease recurrence, but its role remains unclear in most conditions that we treat with transplantation. Here, Dr. Hourigan presents an overview of minimal residual disease (MRD) measurement in hematologic malignancies and the applicability of MRD-based post-transplantation interventions. Dr. McCarthy reviews current knowledge of maintenance therapy in the autologous transplantation context, with emphasis on immunologic interventions and immune modulation strategies designed to prevent relapse. Dr. de Lima discusses current lines of investigation in disease recurrence prevention after allogeneic transplantation, focusing on acute myeloid leukemia and myelodysplastic syndrome.

Original languageEnglish (US)
Pages (from-to)154-163
Number of pages10
JournalBiology of Blood and Marrow Transplantation
Issue number2
StatePublished - Feb 2014
Externally publishedYes


  • Hematology malignancy
  • Immune system
  • Leukemia
  • Lymphoma
  • Residual disease

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Back to the future! the evolving role of maintenance therapy after hematopoietic stem cell transplantation'. Together they form a unique fingerprint.

Cite this